BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 37444536)

  • 1. Appendiceal Mucinous Neoplasms: From Clinic to Pathology and Prognosis.
    González Bayón L; Martín Román L; Lominchar PL
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which classification system defines best prognosis of mucinous neoplasms of the appendix with peritoneal dissemination: TNM vs PSOGI?
    Martín-Román L; Lozano P; Gómez Y; Fernández-Aceñero MJ; Vasquez W; Palencia N; González-Bayón L
    J Clin Pathol; 2023 Apr; 76(4):266-273. PubMed ID: 34725195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between PSOGI pathological classification and survival outcomes of patients with pseudomyxoma peritonei treated using cytoreductive surgery and HIPEC: national referral centre experience and literature review.
    Martín-Román L; Hannan E; Faraz Khan M; Müller AS; Shields C; Aird J; Moran B; Mulsow J
    Pleura Peritoneum; 2023 Jun; 8(2):65-74. PubMed ID: 37304162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining stage in mucinous tumours of the appendix with peritoneal dissemination: the importance of grading terminology: systematic review.
    Martín-Román L; Lozano P; Vásquez W; Palencia N; Gómez Y; Fernández-Aceñero MJ; González-Bayón L
    BJS Open; 2021 Jul; 5(4):. PubMed ID: 34355239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Garach NR; Kusamura S; Guaglio M; Bartolini V; Deraco M; Baratti D
    Eur J Surg Oncol; 2021 May; 47(5):1132-1139. PubMed ID: 33280949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
    Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 7th Edition of the AJCC Staging Classification Correlates with Biologic Behavior of Mucinous Appendiceal Tumor with Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Milovanov V; Sardi A; Studeman K; Nieroda C; Sittig M; Gushchin V
    Ann Surg Oncol; 2016 Jun; 23(6):1928-33. PubMed ID: 26714951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic value of clinical and pathological characteristics in 48 women with pseudomyxoma peritonei].
    Lu YY; Guo AT; Liu AJ; Shi HY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):595-601. PubMed ID: 24199925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasms.
    Erstad DJ; Robinson KA; Beaty K; Rafeeq S; Chiang YJ; Raghav K; Shen JP; Overman MJ; Foo WC; Taggart MW; Mansfield PF; Royal RE; Fournier KF; Scally CP
    Langenbecks Arch Surg; 2023 Feb; 408(1):110. PubMed ID: 36853519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process.
    Carr NJ; Cecil TD; Mohamed F; Sobin LH; Sugarbaker PH; González-Moreno S; Taflampas P; Chapman S; Moran BJ;
    Am J Surg Pathol; 2016 Jan; 40(1):14-26. PubMed ID: 26492181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a Nomogram to Predict Recurrence in Patients with Mucinous Neoplasms of the Appendix with Peritoneal Dissemination After Cytoreductive Surgery and HIPEC.
    Martín Román L; Lozano P; Baratti D; Kusamura S; Deraco M; Vásquez W; González Bayón L
    Ann Surg Oncol; 2022 Nov; 29(12):7553-7563. PubMed ID: 35876926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Update on the Diagnosis, Grading, and Staging of Appendiceal Mucinous Neoplasms.
    Valasek MA; Pai RK
    Adv Anat Pathol; 2018 Jan; 25(1):38-60. PubMed ID: 29016471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms.
    Abudeeb H; Selvasekar CR; O'Dwyer ST; Chakrabarty B; Malcolmson L; Renehan AG; Wilson MS; Aziz O
    Surg Endosc; 2020 Dec; 34(12):5516-5521. PubMed ID: 31993814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validating the PSOGI classification of peritoneal disease from non-carcinoid epithelial appendiceal neoplasms in the curative and palliative setting: an observational retrospective study.
    Farrokhnia N; Benoni H; Ghanipour L; Cashin PH
    J Gastrointest Oncol; 2022 Apr; 13(2):859-870. PubMed ID: 35557579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite Experience.
    Solomon D; Bekhor E; Leigh N; Maniar YM; Totin L; Hofstedt M; Aycart SN; Carr J; Ballentine S; Magge DR; Golas BJ; Pai RK; Polydorides AD; Bartlett DL; Labow DM; Choudry HA; Sarpel U
    Ann Surg Oncol; 2020 Jan; 27(1):147-153. PubMed ID: 31385130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucinous appendiceal neoplasms: classification, imaging, and HIPEC.
    Bartlett DJ; Thacker PG; Grotz TE; Graham RP; Fletcher JG; VanBuren WM; Iyer VR; Fidler JL; Menias CO; Wasif N; Sheedy SP
    Abdom Radiol (NY); 2019 May; 44(5):1686-1702. PubMed ID: 30610247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
    Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
    JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological Subtype Remains a Significant Prognostic Factor for Survival Outcomes in Patients With Appendiceal Mucinous Neoplasm With Peritoneal Dissemination.
    Huang Y; Alzahrani NA; Chua TC; Morris DL
    Dis Colon Rectum; 2017 Apr; 60(4):360-367. PubMed ID: 28267002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations in the management of epithelial appendiceal neoplasms and peritoneal dissemination from mucinous tumours (pseudomyxoma peritonei).
    Barrios P; Losa F; Gonzalez-Moreno S; Rojo A; Gómez-Portilla A; Bretcha-Boix P; Ramos I; Torres-Melero J; Salazar R; Benavides M; Massuti T; Aranda E
    Clin Transl Oncol; 2016 May; 18(5):437-48. PubMed ID: 26489426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.